HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $250

Benzinga · 1d ago
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $455 to $250.